socalTECH
MARCH 18, 2011
San Diego-based Websense is reportedly considering a sale of the company, according to a report this week in the Wall Street Journal. The Journal reports Websense has hired investment banking firm Qatalyst Partners on the sale. According to the WSJ, the firm is looking to get around $1B for the company.
Xconomy
AUGUST 17, 2016
Histogen, a San Diego-based regenerative medicine company with technology for growing skin cells and related products, said it has raised $6 million from an affiliate of Huapont Life Sciences, a healthcare products company based in Chongqing, China.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
FEBRUARY 5, 2018
When those investors do open their wallets, they’re shunning risky investments in favor of what the Wall Street Journal called “the upper echelon of highly valued startups” such as Airbnb and WeWork. You could make a good case that these investors are taking the “venture” out of “venture capital.”
Xconomy
JULY 26, 2016
The financing includes both new investment funding and a conversion of debt to equity, according to a notation in the filing. Adding to the confusion, the most-recent MoneyTree Report on San Diego venture capital activity shows that Ostendo raised almost $10 million in VC funding during the second quarter.
Xconomy
JULY 17, 2020
If it seems like biotech investments have defied the financial headwinds of the pandemic, maybe it’s because they have. In the second quarter, 16 of the top 25 largest early-stage venture capital deals were investments in life science companies. It’s the biotech sector’s largest proportion of the top 25.
Tech.Co
NOVEMBER 28, 2017
Milwaukee County Executive Chris Abele and Oscar-winning filmmaker John Ridley confirmed their plans in a recent joint statement to the Journal Sentinel , but haven’t explained much else about the incubator, which could help along the (relatively) under-explored film startup niche if completed. Brooklyn Foodworks.
Xconomy
AUGUST 16, 2016
A recent Wall Street Journal article that raised the possibility of Biogen as the target of another huge pharma buyout cited the lack of productivity as a major driver of M&A in the pharmaceutical industry. The authors made the point that, given the size of companies today, a single garden-variety blockbuster hardly moves the needle.
Expert insights. Personalized for you.
145 
Let's personalize your content